IUC26671-87

Abstract Code: IUC26671-87   Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026 S. Buchanan 1, G. Clements 1, C. Forde 1, A. Clayton 1 (1) Northern Ireland cancer centre, Belfast – United Kingdom   Objective: Adjuvant...

IUC26666-91

Abstract Code: IUC26666-91   Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC) R. Winayak 1, X. Li 1, N.J. Salgia...

IUC26658-92

Abstract Code: IUC26658-92   Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations D. Khanna 1, T. Dey 2, E. Blanchard-Cavagis 3,...

IUC26657-91

Abstract Code: IUC26657-91   Sex-based Disparities in Metastatic Renal Cell Carcinoma: Real-World Data from Meet-URO33 Study. M. Zinelli Ronzoni 1, M. Maffezzoli 1, E. Lai 2, E. Verzoni 3, C. Lolli 4, M. Di Napoli 5, A. Signori 6, S. Buti 1, S.E. Rebuzzi 7, D....

IUC26628-89

Abstract Code: IUC26628-89   Real-World Outcomes of Adjuvant Pembrolizumab in Renal Cell Carcinoma: A Single-Centre Experience    O. Okuma 1, C. Nwankwo 1, M. Cortez 1, M. Chipuriro 1, K. Kumar 1 (1) James Cook University Hospital, Middlesbrough – United...

IUC26562-86

Abstract Code: IUC26562-86   Integrating Transcriptomic Profiles and Clinical Outcomes Across MEET-URO Risk Groups in Metastatic Renal Cell Carcinoma: A Comparative Analysis with the IMDC Framework G. Neola 1, N. Salgia 2, A. Moradi 2, S.E. Rebuzzi 3, P. Rescigno...
error: Content is protected !!